The world is grappling with an increasing burden of kidney disease, affecting over 85 million individuals globally. As kidney function declines, particularly when it falls below 15% of its normal capacity, the necessity for kidney replacement therapies, such as dialysis and transplantation, becomes critical. The US Renal Data System indicates a staggering wait of nearly four years for a kidney transplant in the United States, where 94,000 individuals are on the waiting list, the longest for any organ transplant. Remarkably, 15% of these have been waiting over five years.
Disparity in Global Access to Kidney Replacement Therapy
Accessibility to life-saving kidney replacement therapy varies significantly worldwide, particularly affecting low- and lower-middle-income countries. While high-income countries show better management with only 40% of patients lacking treatment, in low-income regions, this number soars to 96%. This disparity results in over 2 million deaths annually due to inadequate access to necessary care.
Vast Differences in Treatment Availability
Chronic dialysis, a lifeline for those with end-stage kidney disease (ESKD), presents a stark contrast in availability across different economic regions. From as high as 3251 pmp in Taiwan to a low of 0.5 pmp in Tanzania, the difference in dialysis prevalence is enormous. Similarly, the frequency of kidney transplants varies greatly, with Portugal having 693 pmp compared to only 3.1 pmp in the Bahamas.
The Role of Dialysis Centers
Dialysis centers are essential in managing kidney disease, offering both haemodialysis (HD) and peritoneal dialysis (PD). HD, though common, increases infection risks due to the frequent use of catheters or needles. PD and home dialysis represent safer, less costly alternatives, highlighting the need for dialysis centers to provide necessary equipment, training, and support.
Chronic Kidney Disease: A Public Health Crisis
Chronic kidney disease (CKD) and its advanced form, ESKD, impose significant healthcare costs and impact quality of life. The US alone spends $84 billion on CKD and $36 billion on ESKD annually. Early detection and management of CKD are crucial to prevent progression to ESKD, where the cost of HD can reach up to $100,000 per patient per year.
Promising Outlook for the Dialysis Center Market
By 2030, it is projected that 14.5 million people will need treatment for ESKD, yet only 5.4 million are likely to receive it due to various socio-economic and political factors. In 2019, US government expenditures on kidney disease reached a substantial $121 billion, nearly a quarter of all Medicare payments for health services. This burgeoning demand signifies a robust market opportunity for dialysis centers.
Competitive Landscape and Market Dynamics
The dialysis center market is dominated by major players like DaVita and Fresenius, which control a significant share of the US market. Other notable players include US Renal Care and American Renal Associates. The market's growth is driven by the increasing prevalence of kidney disease and associated conditions like diabetes. Efficient operations and strategic marketing are crucial for profitability, with large companies benefiting from economies of scale.
The Critical Role of Health Information Systems and Regulatory Entities
Efforts to prevent ESKD through better detection strategies are vital. The introduction of the Redsense Alarm in 2020, a device monitoring blood leakage during HD, exemplifies innovation in patient safety. Comprehensive health information systems and renal registries, especially in lower-income countries, are essential for informed decision-making and policy formulation. Regulatory bodies like the ASN, ERA-EDTA, and ISN play pivotal roles in education, advocacy, and training.
Know More:https://www.fairfieldmarketresearch.com/report/kidney-dialysis-centres-market
Comments